Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18133732 | 1.00 | CACNA1B (0.51) | CACNA1BKLK5KLK7SYKMAPT | |
| SCHEMBL7299670 | 0.92 | KLK5 (0.53) | KLK5KLK7SYKMAPTPPARA | |
| SCHEMBL917118 | 0.90 | MAPT (0.49) | CACNA1BKLK5KLK7SYKMAPT | |
| SCHEMBL19829636 | 0.90 | KLK5 (0.50) | KLK5KLK7SYKMAPTPPARA | |
| SCHEMBL30378756 | 0.89 | CACNA1B (0.51) | CACNA1BKLK5KLK7SYKMAPT | |
| SCHEMBL19833252 | 0.87 | KLK7 (0.48) | KLK5KLK7SYKMAPTPPARA | |
| SCHEMBL18133701 | 0.87 | KLK7 (0.48) | KLK5KLK7SYKMAPTPPARA | |
| SCHEMBL1826013 | 0.84 | SYK (0.47) | KLK5KLK7SYKMAPTTP53 | |
| SCHEMBL4878275 | 0.84 | MAPT (0.60) | CACNA1BKLK5KLK7SYKMAPT | |
| SCHEMBL390389 | 0.83 | CACNA1B (0.45) | CACNA1BMAPTTP53PPARACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | CACNA1B 1078/4885KLK5 3218/4885KLK7 2573/4885 |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | CACNA1B 1078/4885KLK5 3218/4885KLK7 2573/4885 |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | BRD4, BICRA, NDUFC2 | CACNA1B 1078/4885KLK5 3218/4885KLK7 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.